Vaccination as a key element to combat the epidemic and pandemic

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Today, about 30 infectious diseases can be prevented by vaccination. Successful vaccination of the population can prevent at least 2-3 million deaths per year from various infections. Unfortunately, to date, anti-epidemic measures throughout the world have led to the complete elimination of only one infectious disease - smallpox. At the same time, the incidence and mortality from infectious diseases remains at a fairly high level, and WHO has compiled a list of 9 infections that cannot be prevented by vaccination today, and the development of vaccines for the prevention of these diseases is one of the priorities of public health. The WHO also believes that vaccine development must move faster as the world prepares for the emergence of a new pandemic of yet unknown disease, «Disease X». In this regard, the production of new vaccines presents enormous challenges in terms of studying the target pathogens for future vaccine candidates, as well as achieving the desired results to prevent the development of epidemics and pandemics.

Full Text

Restricted Access

About the authors

Alexey M. Osadchuk

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, Moscow

Email: a.m.osadchuk@2020mail.ru
ORCID iD: 0000-0002-8488-9235
Scopus Author ID: 24576966600

MD, professor, professor of the Department of gastroenterology, Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Russian Federation, 121552, Moscow,22 Akademika Pavlova Str.

Irina D. Loranskaya

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, Moscow

Email: gastromapo@yandex.ru
ORCID iD: 0000-0002-3681-4132
Scopus Author ID: 36164230100

MD, professor, head of the Department of gastroenterology, Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia

Russian Federation, 121552, Moscow,22 Akademika Pavlova Str.

Mikhail A. Osadchuk

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

Author for correspondence.
Email: osadchuk.mikhail@yandex.ru
ORCID iD: 0000-0003-0485-6802
Scopus Author ID: 6701741609

MD, professor, head of the Department of polyclinic therapy, I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University

Russian Federation, 119333, Moscow,10 Fotievoy Str.

References

  1. Plotkin S. History of vaccination. Proc Natl Acad Sci USA. 2014; 111(34): 12283–87. https://dx.doi.org/10.1073/pnas.1400472111.
  2. Gualano M.R., Olivero E., Voglino G. et al. Knowledge, attitudes and beliefs towards compulsory vaccination: A systematic review. Hum Vaccin Immunother. 2019; 15(4): 918–31. https://dx.doi.org/10.1080/21645515.2018.1564437.
  3. Excler J.-L., Saville M., Berkley S., Kim J.H. Vaccine development for emerging infectious diseases. Nat Med. 2021; 27(4): 591–600. https://dx.doi.org/10.1038/s41591-021-01301-0.
  4. Renosa M.D.C., Landicho J., Wachinger J. et al. Nudging toward vaccination: a systematic review. BMJ Glob Health. 2021; 6(9): e006237. https://dx.doi.org/10.1136/bmjgh-2021-006237.
  5. Li X., Mukandavire C., Cucunuba Z.M. et al. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: A modelling study. Lancet. 2021; 397(10272): 398–408. https://dx.doi.org/10.1016/S0140-6736(20)32657-X.
  6. Barrett S., Hoel M. Optimal disease eradication. Environ Dev Econ. 2007; 12(5): 627–52. https://dx.doi.org/10.1017/S1355770X07003816.
  7. Autran B., Launay O., Floret D. Vaccinations. EMC – Maladies infectieuses. 2016; Article 8-002-Q-10: 1-14. https://dx.doi.org/10.1016/S1166-8598(15)49465-7.
  8. Canoui E., Launay O. Histoire et principes de la vaccination. Rev Mal Respir. 2019; 36(1): 74–81. [Canoui E., Launay O. History and principles of vaccination. Rev Mal Respir. 2019; 36(1): 74–81 (In French)]. https://dx.doi.org/10.1016/j.rmr.2018.02.015.
  9. Zepp F. Principles of vaccination. Methods Mol Biol. 2016; 1403: 57–84. https://dx.doi.org/10.1007/978-1-4939-3387-7_3.
  10. Gasper D.J., Tejera M.M., Suresh M. CD4 T-cell memory generation and maintenance. Crit Rev Immunol. 2014; 34(2): 121–46. https://dx.doi.org/10.1615/critrevimmunol.2014010373.
  11. Eibel H., Kraus H., Sic H. et al. B cell biology: An overview. Curr Allergy Asthma Rep. 2014; 14(5): 434. https://dx.doi.org/10.1007/s11882-014-0434-8.
  12. Merle N.S., Noe R., Halbwachs-Mecarelli L. et al. Complement system part II: Role in immunity. Front Immunol. 2015; 6: 257. https://dx.doi.org/10.3389/fimmu.2015.00257.
  13. Trofin F., Nastase E.V., Iancu L.S. et al. Anti-RBD IgA and IgG response and transmission in breast milk of anti-SARS-CoV-2 vaccinated mothers. Pathogens. 2022; 11(3): 286. https://dx.doi.org/10.3390/pathogens11030286.
  14. Pollard A.J., Bijker E.M. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021; 21(2): 83–100. https://dx.doi.org/1038/s41577-020-00479-7.
  15. Timing and spacing of immunobiologics. General best practice guidelines for immunization: Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Updated September 8,2022. CDC. Accessed, October,21,2022. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html (date of access – 01.03.2023).
  16. Dai X., Xiong Y., Li N., Jian C. Vaccine types. March 5th,2019. https://dx.doi.org/10.5772/intechopen.84626. Accessed, October,21,2022. URL: https://www.intechopen.com/chapters/65813 (date of access – 01.03.2023).
  17. Jaurigue J.A., Seeberger P.H. Parasite carbohydrate vaccines. Front Cell Infect Microbiology. 2017; 7: 248. https://dx.doi.org/10.3389/fcimb.2017.00248.
  18. Pulendran B.S., Arunachalam P., O’Hagan D.T. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6): 454–75. https://dx.doi.org/10.1038/s41573-021-00163-y.
  19. Xia S., Zhang Y., Wang Y. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020; 21(1): 39–51. https://dx.doi.org/10.1016/S1473-3099(20)30831-8.
  20. Zhang Y., Zeng G., Pan H. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(2): 181–92. https://dx.doi.org/10.1016/ S1473-3099(20)30843-4.
  21. Djurisic S., Jakobsen J.C., Petersen S.B. et al. Aluminium adjuvants used in vaccines. Cochrane Database Syst Rev. 2018; (7): CD013086. https://dx.doi.org/10.1002/14651858.CD013086.
  22. Gilsdorf J.R. Hib vaccines: Their impact on Haemophilus influenzae type b disease. J Infect Dis. 2021; 224(12 Suppl 2): S321–S330. https://dx.doi.org/10.1093/infdis/jiaa537.
  23. Desai A.N., Majumder M.S. What is herd immunity? JAMA. 2020; 324(20): 2113. https://dx.doi.org/10.1001/jama.2020.20895.
  24. Bolotin S., Wilson S., Murti M. Achieving and sustaining herd immunity to SARS-CoV-2. CMAJ. 2021; 193(28): E1089. https://dx.doi.org/10.1503/cmaj.210892.
  25. Vaccine-preventable diseases. European Centre for Disease Prevention and Control. Accessed, October,21,2022. URL: https://www.ecdc.europa.eu/en/vaccine-preventable-diseases (date of access – 01.03.2023).
  26. Bloom D.E., Cadarette D. Infectious disease threats in the twenty-first century: Strengthening the global response. Front Immunol. 2019; 10: 549. https://dx.doi.org/10.3389/fimmu.2019.00549.
  27. Hatchett R. Prepare to prevent: Developing pandemic-busting vaccines against «Disease X». United Nations. UN Chronicle. 27 December 2021. Accessed, October,21,2022. URL: https://www.un.org/en/un-chronicle/prepare-prevent-developing-pandemic-busting-vaccines-against-%E2%80%9Cdisease-x%E2%80%9D (date of access – 01.03.2023).
  28. WHO. 2018 annual review of diseases prioritized under the research and development blueprint. 6–7 February 2018. Geneva, Switzerland. Accessed, October,21,2022. URL: https://www.who.int/news-room/events/detail/2018/02/06/default-calendar/2018-annual-review-of-diseases-prioritized-under-the-research-anddevelopment-blueprint (date of access – 01.03.2023).
  29. WHO. Pandemic influenza preparedness framework: For the Sharing of influenza viruses and access to vaccines and other benefits. 2011. Accessed, October,21,2022. URL: https://apps.who.int/iris/bitstream/handle/10665/44796/9789241503082_eng.pdf (date of access – 01.03.2023).
  30. Shrestha Y., Shivalingegowda R.K., Avinash M.J. et al. The rise in antimicrobial resistance: An obscure issue in COVID-19 treatment. PLOS Glob Public Health. 2022; 2(7): e0000641. https://dx.doi.org/10.1371/journal.pgph.0000641.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies